What is Korro Bio Inc. Annual Net Profit?

Korro Bio Inc. Annual Net Profit fell 2.97% in the last year to $83.58 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

What is Korro Bio Inc. Price to Earning Ratio?

Korro Bio Inc. Price to Earning Ratio is -1.44, which is negative.

What is Korro Bio Inc. Stock Price?

Korro Bio Inc. Stock Price fell 81.03% and underperformed its sector by 77.28% in the past year.

What is Korro Bio Inc. Quarterly Net profit?

Korro Bio Inc. Quarterly Net profit rose 16.62% YoY to $21.2 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

What is Korro Bio Inc. Debt to Equity Ratio?

Korro Bio Inc. Debt to Equity Ratio of 0.28 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Korro Bio Inc. Return on Equity(ROE)?

Korro Bio Inc. Return on Equity(ROE) for the last financial year was -50.61%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Korro Bio Inc. Mutual Fund Holding?

Korro Bio Inc. Mutual Fund Holding increased by 2.48% in the last quarter to 32.83.

What is Korro Bio Inc. Institutional Holding?

Korro Bio Inc. Institutional Holding remained the same in the last quarter at 89.55%.

How is the Korro Bio Inc. today?

The Korro Bio Inc. today is trading in the down by -14.07% at 12.83.

How has Korro Bio Inc. performed historically?

The Korro Bio Inc. is currently trading down -14.07% on an intraday basis in the past week the index fell -26.31%. The index has been down -66.56% in the past quarter and fell -81.03% in the past year. You can view this in the overview section.

Korro Bio Inc. XNAS: KRRO

Korro Bio Inc. Live Share Price Today, Share Analysis and Chart

Name: Korro Bio Inc.: Is Infosys Ltd. worth buying?
Item: Korro Bio Inc.
Rating: 0.78925
Author: Trendlyne DVM scores

Download real time

12.83 -2.10 (-14.07%)

New 52W Low in past week

57,272 XNAS Volume

XNAS 08 Apr, 2025 5:30 PM (EDT)

Korro Bio Inc. Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	120.5
PE TTM Negative PE TTM Unavailable in chosen country	-1.4
PEG TTM High in industry Unavailable in chosen country	0.5
Price to Book Below industry Median Unavailable in chosen country	0.8
Institutional holding current Qtr % High in industry Unavailable in chosen country	89.6
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	16.6
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-3
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-1,014.5
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-4,047.1
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-59.7
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-50.6
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-37.3

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

13.5 / 100

Technically Bearish

18.1 / 100

139

1Yr Price target upside is 981%

8 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Korro Bio Inc. Stock Price Analysis

Day Price Range -14.1% 1 Day return Unavailable in chosen country	12.8 (LTP) 12.616.2 LowHigh
Week Price Range -26.3% 1 Week return Unavailable in chosen country	12.8 (LTP) 1218.3 LowHigh
Month Price Range -42.5% 1 Month return Unavailable in chosen country	12.8 (LTP) 1228.5 LowHigh
52 Week Price Range -81.0% 1 Year return Unavailable in chosen country	12.8 (LTP) 1298 LowHigh

View full Share Price History

Korro Bio Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

EPS forecast

QUARTER
ANNUAL

Current EPS

-9.4

Avg. Estimate

-10.5

Low Estimate

-11.9

High Estimate

-8.7

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 12.1% in FY25

Consensus Recommendation

8 ANALYST Recommendations

BUY

The consensus recommendation from 8 analysts for Korro Bio Inc. is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Korro Bio Inc. Stock Analysis

Korro Bio Inc. stock analysis with key metrics, changes, and trends.

Korro Bio Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$83.58 M	2.97%	negative	Annual Net Profit fell 2.97% in the last year to $83.58 M. Its sector's average net profit growth for the last fiscal year was -32.62%.
Price to Earning Ratio	-1.44	-	negative	Price to Earning Ratio is -1.44, which is negative.
Stock Price	$12.83	-81.03%	negative	Stock Price fell 81.03% and underperformed its sector by 77.28% in the past year.
Quarterly Net profit	$21.2 M	16.62%	positive	Quarterly Net profit rose 16.62% YoY to $21.2 M. Its sector's average net profit growth YoY for the quarter was -47.55%.
Debt to Equity Ratio	0.28	-	positive	Debt to Equity Ratio of 0.28 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-50.61 %	-50.61%	negative	Return on Equity(ROE) for the last financial year was -50.61%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	32.83 %	2.48%	positive	Mutual Fund Holding increased by 2.48% in the last quarter to 32.83.
Institutional Holding	89.55 %	0%	neutral	Institutional Holding remained the same in the last quarter at 89.55%.

VIEW LESS

Loading data..

Korro Bio Inc. - Company Profile

What does Korro Bio Inc. do?

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Korro Bio Inc. Management structure

All Gross Remunerations are in USD

Dr. Ram Aiyar, M.B.A.,PhD

Director, President and Chief Executive Officer

2025

Gross Remuneration

Year

Mr. Vineet Agarwal, M.B.A.

Chief Financial Officer and Principal Accounting Officer

2025

Gross Remuneration

Year

Mr. Oliver Dolan

Senior Vice President, Finance and Principal Accounting Officer

2025

Gross Remuneration

Year

Korro Bio Inc. Board of directors

All Gross Remunerations are in USD

Dr. Ram Aiyar, M.B.A.,PhD

Director, President and Chief Executive Officer

2025

Gross Remuneration

Year

Korro Bio Inc. Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

Korro Bio Inc. Key Metrics

Market Capitalization

PE TTM

PEG TTM

RoA Annual %

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Korro Bio Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Korro Bio Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

EPS forecast

EPS is expected to reduce by 12.1% in FY25

Consensus Recommendation

The consensus recommendation from 8 analysts for Korro Bio Inc. is BUY

Korro Bio Inc. Stock Analysis

Korro Bio Inc. stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 2.97% in the last year to $83.58 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

Price to Earning Ratio is -1.44, which is negative.

Stock Price fell 81.03% and underperformed its sector by 77.28% in the past year.

Quarterly Net profit rose 16.62% YoY to $21.2 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

Debt to Equity Ratio of 0.28 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -50.61%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 2.48% in the last quarter to 32.83.

Institutional Holding remained the same in the last quarter at 89.55%.

Korro Bio Inc. - Company Profile

What does Korro Bio Inc. do?

Korro Bio Inc. Management structure

Dr. Ram Aiyar, M.B.A.,PhD

Director, President and Chief Executive Officer

Mr. Vineet Agarwal, M.B.A.

Chief Financial Officer and Principal Accounting Officer

Mr. Oliver Dolan

Senior Vice President, Finance and Principal Accounting Officer

Korro Bio Inc. Board of directors

Dr. Ram Aiyar, M.B.A.,PhD

Director, President and Chief Executive Officer

Korro Bio Inc. FAQ

How is Korro Bio Inc. today?

Korro Bio Inc. today is trading in the red, and is down by -14.07% at 12.83.

How has Korro Bio Inc. performed historically?

Korro Bio Inc. is currently trading down -14.07% on an intraday basis. In the past week the stock fell -26.31%. stock has been down -66.56% in the past quarter and fell -81.03% in the past year. You can view this in the overview section.